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Abstract Mutations in the NPHS2 gene encoding podocin
are associated with steroid-resistant nephrotic syndrome
(SRNS) in childhood. Patients usually present with focal
segmental glomerulosclerosis (FSGS). It is unclear to what
extent SRNS due to NPHS2 mutations predisposes to
recurrence of proteinuria/FSGS after renal transplantation
(RTx). A 4-year-old girl with infantile SRNS was started
on peritoneal dialysis because of end-stage renal disease
due to FSGS. Mutational screening of the patient and her
parents revealed a novel single nucleotide deletion in exon
8 of the NHPS2 gene (948delT), for which the patient
was homozygous and her parents confirmed heterozygous
asymptomatic carriers. At the age of 4.5 years the patient
received a renal graft from her mother. On day 7 after
RTx, the patient developed progressive proteinuria (urine
protein/creatinine ratio 2.4 g/g), which responded within
1 week to prednisone pulse therapy, an increased cyclo-
sporin A dosage, and ramipril therapy. The patient has
maintained stable graft function and no further recurrence
of proteinuria has been observed. In conclusion, patients
with SRNS due to NPHS2 mutations are not protected
from recurrence of proteinuria after RTx. The quick re-
sponse to increased immunosuppression in our patient
suggests an immune-mediated pathomechanism for recur-
rence of proteinuria.
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Introduction
Focal segmental glomerulosclerosis (FSGS) is one of the
most common histological findings in childhood steroid-
resistant nephrotic syndrome (SRNS). FSGS represents
a pool of clinically and genetically distinct disorders.
Recently, several genes and their corresponding gene
products, such as nephrin and alpha-actinin-4, have been
demonstrated to be involved in the pathogenesis of
inherited forms of SRNS and FSGS [1]. Mutations in the
NPHS2 gene encoding the membrane-bound protein
podocin were identified as one of the most common
causes of SRNS. Homozygous or compound heterozygous
mutations in the NPHS2 gene have been demonstrated in
up to 30% of patients with sporadic or familial SRNS and
FSGS presenting in childhood [2, 3]. Moreover, it has
been proposed that patients with SRNS due to NPHS2
mutations will be protected from recurrence of protein-
uria/FSGS after renal transplantation (RTx) [3]. This
would have important consequences for graft survival and
overall prognosis of these patients. At variance with this
hypothesis, we report on a 4-year-old girl presenting with
SRNS due to FSGS caused by a novel homozygous
mutation of the NPHS2 gene who developed heavy
proteinuria early after living-related RTx.
Case report
A 4-year-old girl had been suffering from recurrent upper airway
tract infections from early infancy. At the initial presentation at
the age of 6 months, clinical work-up revealed heavy proteinuria
(4.4 g/l), hematuria (60/l), and hypogammaglobulinemia (IgG,
0.5 g/l). At this time, blood pressure and serum creatinine levels
were normal. Since the patient was resistant to steroid treatment
(pred-nisone 2 mg/kg per day for 4 weeks followed by three
methylprednisolone pulses 1 g/m2 per day), a renal biopsy was
performed at the age of 15 months, revealing FSGS (Fig. 1).
Despite treatment with cyclosporin A (blood trough levels 80–
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120 ng/ml) for 2 years, seven pulses of cyclophosphamide (0.5 g/m2
per month) and methylprednisolone (1 g/m2 for 3 days), and
angiotensin converting enzyme inhibitors, the patient showed
persistent nephrotic syndrome and progressive renal failure. At
the age of 4 years the patient was started on peritoneal dialysis
because of end-stage renal disease, and was referred to our hospital.
Mutational screening of the patient and her parents was
performed by semi-automatic sequencing after DNA isolation from
peripheral leukocytes as reported previously [3]. This revealed a
novel single nucleotide deletion in exon 8 of the NPHS2 gene
(948delT) (Fig. 2). The patient was found to be homozygous and,
accordingly, her parents were both heterozygous for this mutation.
As a formal consequence, this frame shift abolishes in-frame
reading of the last regular 204 nucleotides and instead introduces a
premature stop 93 bases after the single nucleotide deletion
encoding a prematurely truncated protein (L347X).
At the age of 4.5 years the patient received a renal graft from
her mother who had been confirmed to be heterozygous for the
same mutation, but had no evidence of renal disease. The patient
was anuric at the time of RTx. RTx was performed without
technical problems, and graft function was excellent, with a daily
urine output ranging from 1,200 ml to 1,600 ml. Post-transplant
immunosuppression consisted of cyclosporin A (blood trough
levels 180–210 ng/ml), mycophenolate mofetil (blood trough levels
1–3 g/ml), and prednisolone. After RTx, daily assessment for
proteinuria was performed. On day 7 after RTx, the patient
developed progressive proteinuria (urine protein/creatinine ratio
2.4 g/g, urine albumin/creatinine ratio 1.1 g/g) (Fig. 3). The patient
showed no edema, hematuria, or hypertension, the serum creatinine
was 40 mol/l, and the serum albumin was 3.0 g/dl. Patency of
renal vessels was shown by Doppler ultrasonography.
The proteinuria responded within 1 week to methylprednisolone
pulse therapy (500 mg on 3 consecutive days), an increased
cyclosporin A dosage (blood trough levels 200–250 ng/ml), and
ramipril therapy (3.75 mg/day) (Fig. 3). Because of the rapid
response of proteinuria to treatment, renal biopsy was not per-
formed. Histological examination of a protocol biopsy performed
Fig. 1 a Light microscopy of the kidney biopsy revealed global
glomerulosclerosis (arrow) in 5 of 12 glomeruli (periodic acid-
Schiff, x200). Immunofluorescence microscopy revealed discrete
mesangial IgM deposits and negative results for C3, IgA, and IgG
(not given). Taken together the histological findings suggest
advanced focal segmental glomerulosclerosis already leading to
global sclerosis in some affected glomeruli. b Electron microscopy
showing normal glomerular basement membrane, effacement of the
visceral epithelial cell foot processes (arrow)
Fig. 2 Genomic organization of the NPHS2 gene. The gene
structure is displayed with its intron-exon boundaries and its gene
product, podocin. The encountered mutation in our patient
(948delT) is marked and the gene product, a prematurely truncated
protein, is shown schematically. Asterisks mark the localization of
the NPHS2 mutations reported to date. Exons and untranslated
regions (UTRs) are proportionally displayed according to their
length, introns are not
Fig. 3 Course of proteinuria after renal transplantation (RTx). The
marked proteinuria that was first noted on day 7 post RTx
responded within 1 week to methylprednisolone pulse therapy and
increased cyclosporin A dosage
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6 months post RTx (light microscopy) showed no glomerular or
tubular abnormalities, and negative immunofluorescence with
antibodies to IgG, IgM, IgA, fibrinogen, C3, C4d, and C5b-9.
Thereafter, the cyclosporin A dosage was reduced in order to
achieve blood trough levels of 100–150 ng/ml. During further
follow-up for 9 months her graft function has remained excellent
(creatinine clearance 98 ml/min per 1.73 m2) and no further
recurrence of proteinuria has been observed. The transplant donor
did not show any signs of renal disease before or after RTx.
Discussion
Recurrence of proteinuria after RTx has been described in
30% of pediatric patients suffering from SRNS due to
FSGS. This is of essential therapeutic and socioeconomic
importance because, despite aggressive treatment protocols
(including steroid pulses, cyclosporin A, cyclophospha-
mide, plasma exchange, and immunadsorption), more than
50% of grafts are lost [4]. The almost immediate recur-
rence of proteinuria in children, which is often observed
within the first weeks after RTx, strongly suggests the
presence of a circulating factor producing proteinuria by a
hitherto unknown mechanism. Other diseases causing
recurrence of proteinuria after RTx include de novo
glomerulonephritis and the formation of antibodies to
podocyte proteins, as has been shown in patients with
congenital nephrotic syndrome of the Finnish type [5].
Recently, a study involving a large cohort of patients
with FSGS due to mutations in the NHSP2 gene con-
cluded that these patients will not develop recurrence of
proteinuria after RTx [3]. In contrast, our patient devel-
oped heavy proteinuria early after RTx. In addition, five
other patients with SRNS with homozygous or heterozy-
gous NPHS2 mutations showing early recurrence of
proteinuria after RTx have recently been reported [6, 7,
8]. This phenomenon remains without explanation, espe-
cially since proteinuria in all except one patient responded
well to increased immunosuppression, whereas their ini-
tial SRNS did not. Therefore, it might not be appropriate
to speak of recurrence of the original disease. The origin
of post-transplant proteinuria is currently unknown, but
the early occurrence after RTx strongly argues against a
de novo antibody mediated mechanism. In patients with
the congenital syndrome of the Finnish type, post-trans-
plant proteinuria occurred several months after RTx and
was associated with antibodies to the podocyte protein
nephrin. No anti-podocin antibodies could be detected by
immunoblotting in three SRNS patients showing podocin
mutations and early recurrence of proteinuria after RTx
and no immunoglobin deposits could be detected by renal
histology [8], making an antibody mediated mechanism
rather unlikely.
The underlying mutation (L347X) in our patient was
located close to the C-terminal end of the protein, sug-
gesting that this area is of major importance for proper
protein routing and/or function (e.g., nephrin/podocin in-
teraction). Beside this mutation, two additional mutations
in exon 8 of the NPHS2 gene have been encountered to
date (L327F, 923/2delAA) [9]. All these mutations are of
special interest, since their particular location will serve to
identify important regulatory elements located downstream
of the first changed amino acid of the altered protein. The
NCBI conserved domain search and CDART program
(http://www.ncbi.nlm.nih.gov/Structure) were used to de-
termine the possibility that this frame shift generated novel
amino acid domains in the resulting protein. However, no
known protein motif was identified. This was also the case
for the wild type podocin amino acid sequence, which was
subjected to the same database search. Recently, it has
been shown that podocin co-localizes with several other
podocyte proteins, such as nephrin, so that it is likely that
the C-terminal part harbors essential regions for protein
sorting, membrane targeting, and protein/protein interac-
tion that remain to be determined [10].
In two other patients with SRNS due to a homozygous
NPHS2 mutation showing heavy proteinuria early after
RTx, recurrence of FSGS was proven by renal biopsy.
Both children displayed the same missense mutation
(R138Q) located in exon 3 [6, 7, 8]. From this informa-
tion, it can be hypothesized that recurrence of proteinuria
is not dependent on the localization of the mutation within
the gene. SRNS due to NPHS2 mutations is thought to be
a recessive disease requiring a mutation on both alleles
coding for podocin. Therefore, mutations involving one or
more as yet uncharacterized genes of the podocyte pro-
ducing an additive effect must be postulated in these
patients. Living-related RTx from donors bearing a
heterozygous NPHS2 mutation seems not to be per se
associated with an increased risk of recurrence of pro-
teinuria after RTx in this patient population, although to
our knowledge this case report is the first living-donor
related recurrence of proteinuria in NPHS2 patients. All
other reported patients have undergone cadaveric RTx [6,
7, 8]. Careful clinical work-up of potential transplant
donors who are heterozygous for a NPHS2 mutation, as in
our case, should be performed before and after RTx in
order to exclude glomerular disease leading to progressive
renal failure in the donor after unilateral nephrectomy.
In conclusion, patients with SRNS due to NPHS2
mutations are not protected from recurrence of proteinuria
after RTx. Although the quick response to increased
immunosuppression in our patient suggests an immune-
mediated glomerular disease, the exact mechanism re-
mains to be clarified.
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